At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
eribulin mesylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer
In Brief
A Phase 2 clinical trial evaluating eribulin mesylate for Recurrent Cervical Cancer and 4 related conditions. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedAug 2012
Primary CompletionFeb 2021
Study CompletionDec 2021
TodayJul 2026
First PostedAug 31, 2012
Enrollment StartAug 9, 2012
Primary CompletionFeb 21, 2021
Study CompletionDec 22, 2021
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 13.8 years ago
Interventions
eribulin mesylatedrug
Given IV